Compare Adaptive Biotechnologies Corp (ADPT) vs Core Scientific Inc (CORZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Core Scientific Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Core Scientific Inc trades at $22.04 (market cap $6.85B). The key difference: Core Scientific Inc is far larger — about 2.1× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | CORZ | |
|---|---|---|
Market Cap | $3.33B | $6.85B |
Sector | Health | Technology |
52-Week High | $22.37 | $29.16 |
52-Week Low | $10.24 | $12.51 |
Enterprise Value | $3.19B | $7.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CORZ trades at $22.80, up 6.39% today, while showing bearish technical signals with a net cash outflow of $525.6M in 2025. The company is pivoting from Bitcoin mining to AI colocation, with Q1 2026 colocation revenue surging to $77.5M and gross margins of 57%. Despite missing earnings estimates for three consecutive quarters, analyst consensus remains strongly bullish with 86% buy ratings and a $33.43 price target.
The stock presents a high-risk, high-reward opportunity as the AI infrastructure transition accelerates. Near-term execution risks and negative profitability metrics contrast with substantial growth potential in the AI data center market. Wall Street optimism appears to outweigh current financial challenges, but investors should monitor cash flow improvements and contract execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →
